selexipag 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins receptors agonists, non-prostanoids 5077 475086-01-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • selexipag
  • uptravi
  • ACT-293987
  • NS-304
  • ACT293987
an oral prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin, indicated for the treatment of pulmonary arterial hypertension, selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag, selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP1-4, DP, FP and TP)
  • Molecular weight: 496.63
  • Formula: C26H32N4O4S
  • CLOGP: 4.18
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 101.49
  • ALOGS: -5.06
  • ROTB: 11
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.80 mg O

ADMET properties:

None

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

selexipag